Intestinal Pseudo-obstruction Treatment Market Size & Share, by Type (Acute, Chronic); Treatment (Medication, Surgery, Diet, Decompression); Diagnosis (Physical Exam, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Manometry); Symptoms (Abdominal Pain, Bloating, Diarrhea, Vomiting, Nausea, Constipation); Dosage (Tablet, Injection), Drug Class (Antibiotic, Antidepressants, Antidiarrheal) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5760
  • Published Date: Feb 29, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Intestinal Pseudo-obstruction Treatment Market size is expected to reach USD 37 Billion by the end of 2036, growing at a CAGR of 5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of intestinal pseudo-obstruction treatment crossed USD 23 Billion. The increased frequency of gastrointestinal disease will propel the primary reason behind the growth of the intestinal pseudo-obstruction treatment market. As the macroeconomic prospect degenerates for the automotive industry, a modest return to expansion is anticipated for the latest clients and commercial vehicle sales in the next two years. It is projected that international vehicle sales will expand by 5.1% in 2023 and 3.6% in 2024. Moreover, automakers can project sales to come back to the 90 million+ high water mark in 2025.

Another reason that will propel the intestinal pseudo-obstruction treatment market by the end of 2036 is the cost-effective diagnosis and treatment worldwide. Patient existence was 89% at 1 year and 69% at 5 years with corresponding graft existence of 87% and 56%. Retransplantation was victorious in 86%. The primary treatment is wholesome support to stop malnutrition and antibiotics to cure bacterial infections. ailments that may coexist and deteriorate symptoms of pseudo-obstruction--like gastroparesis (postponed stomach emptying), gastroesophageal reflux, or bacterial gigantism—require to be recognized and cured. The challenges of curing chronic pseudo-obstruction are repeatedly many-sided and comprise the patient and family along with the physician. The physician may recommend a multidisciplinary technique for therapy. A maintenance team might comprise the child's pediatric gastroenterologist, a pediatric pain maintenance specialist, a behavioral expert, and others. In acute cases, surgery to eliminate part of the intestines might be important. In a subset of patients, when pseudo-obstruction is restricted to an isolated segment of the bowel, surgical bypass may be acknowledged. In the most severe cases, when patients getting total parenteral nutrition undergo life-threatening problems like severe infection or liver failure, small bowel relocation may be acknowledged. This technique is challenging and has a lot of related risks. It should only be acknowledged when all other therapy choices have been worn out.

Intestinal Pseudo-obstruction Treatment Market
Get more information on this report: Request Free Sample PDF

Intestinal Pseudo-obstruction Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Impact of the Sedentary Lifestyle   - Sedentary behavior signifies less movement, so fewer calories are scorched. It’s suggested that adults and teens perform at least 2.5 hours of physical activity weekly to limit the opportunity for heart disease. However current studies demonstrate that only one in five people have the exercise they should – this can outcome in unplanned weight gain and possibly obesity. Of the many positive transformations that have happened in their production during the 21st century, one of the adverse prospects has been the kind of appearing and rising trend of a sedentary lifestyle. Related to their grandparents or parents, there is a substantial reduction in physical activity and a rise in health complexities. The indications of a sedentary lifestyle can be both physical and mental, and sometimes they’re so small that it may not even acknowledge they’re emerging. It’s significant to comprehend and recognize the indications so they can make changes to modify your health and quality of life.
  • Advancements in Diagnostic Equipment - A massively low incidence, non-particular clinical symptoms, powerful heterogeneity, and no definitive cause in some patients make CIPO very difficult to diagnose correctly. Imaging and gastrointestinal manometry are usually utilized. Most patients have advanced worsening of their symptoms and require arbitration, and nutritional assessment and treatment are very important to determine the prognosis. With modifications in surgical processes, small bowel transplantation is a possible therapy choice for patients with advanced CIPO; but, the permanent prognosis for CIPO patients stays unsatisfactory. Usually, the disease is rare and tough to diagnose, which leads to clinicians’ shortage of comprehension of the disease and outcomes in a high rate of misdiagnosis. This review explains the features of CIPO and the new developments in diagnosis and therapy, in detail. The objective of their review is to modify clinicians' comprehension of CIPO so that the disease is recognized promptly and precisely, and cured as early as feasible to modify patients’ quality of life.
  • Increasing Emphasis on Patient-Centric Care - Patients are living longer with chronic situations because of these progresses, and their role in health care is transforming from that of an inactive recipient of medical care to an active participant in clinical decision-making. These reasons are now putting the burden on the intricate, expensive, and frequently fragmented U.S. healthcare system to modify quality, as deliberated by patient experience.


  • High Cost of Treatment of Intestinal Pseudo-obstruction - Acute colonic pseudo-obstruction is the clinical syndrome of sharp large bowel dilatation without mechanical impediment that is a significant cause of unwholesomeness and mortality. Intense colonic pseudo-obstruction takes place in hospitalized or institutionalized patients with severe fundamental medical and surgical situations. The pathogenesis of sharp colonic pseudo-obstruction is not realized but possibly results from inequality in the autonomic control of colonic motor function. Metabolic or pharmacological reasons, along with spinal or para-peritoneal trauma, may convert the autonomic rules of colonic operation, taking to unreasonable parasympathetic repression or sympathetic excitement. This disparity results in colonic atony and distension. Prior acknowledgment and suitable maintenance are crucial to limiting unwholesome and death. The mortality rate is projected at 40% when ischemia or puncture appears. The best-studied therapy of sharp colonic pseudo-obstruction is hypodermic neostigmine, which takes prompt colon decompression in the abundance of patients after a single infusion.
  • Side Effects Related to the Medications
  • Lack of Knowledge in People

Intestinal Pseudo-obstruction Treatment Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~USD 23 Billion

Forecast Year Market Size (2036)

~USD 37 Billion

Regional Scope

  • North America (North America, Canada, Mexico)
  • Europe (Germany, Spain, UK, France, Italy, Russia, Others)
  • Asia Pacific (Japan, China, India, Australia, Others)
  • Middle East and Africa (South Africa, UAE, Others)
  • Latin America (Brazil, Argentina, Others)
Get more information on this report: Request Free Sample PDF

Intestinal Pseudo-obstruction Treatment Segmentation

Drug Class (Antibiotic, Antidepressants, Antidiarrheal)

The antibiotic segment in the intestinal pseudo-obstruction treatment market will grow the most by the forecast period and will hold almost 68% because of its extensive use in people across the world to treat intestinal pseudo-obstruction. Doctors cure chronic intestinal pseudo-obstruction with nutrition help, medicines, ease, and sometimes surgery. If a fundamental health issue is causing chronic intestinal pseudo-obstruction, doctors will also cure the basic health issue as required. According to the original description, Ogilvie attributed the large bowel colic to a violation of the sympathetic supply because of retroperitoneal spitefulness leaving the parasympathetic innervation unopposed. The shortage of inhibitory inputs would produce a neuropathophysiological instability leading to fitful colonic contraction causing a hindrance. The proximal bowel would then become heavily dilated under the impact of parasympathetic nerve trails.

Diagnosis (Physical Exam, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Manometry)

The blood test segment in the intestinal pseudo-obstruction treatment market is expected to hold 38% of the revenue share owing to the increasing blood tests to detect the disease of intestinal pseudo-obstruction. Intestinal pseudo-obstruction is an unusual situation that can be tough to diagnose because your symptoms can mimic other maladies. With a team of gastrointestinal motility specialists and a devoted Neurogastroenterology, Motility, and Functional Disorders Program, they surpass in promptly and precisely diagnosing your situation at Stanford Health Care. Once they comprehend the source of your discomfort, they provide customized treatments so you can begin to feel better. A substitute hypothesis acknowledges the potential that tonic hyperactivity of exterior or interior inhibitory neurones may play a crucial role in the pathophysiology of Ogilvie’s syndrome.

Our in-depth analysis of the global intestinal pseudo-obstruction treatment market includes the following segments:


  • Acute
  • Chronic


  • Medication
  • Surgery
  • Diet
  • Decompression


  • Physical Exam
  • Biopsy
  • Blood Test
  • Gastric Emptying Tests
  • Imaging Tests, Manometry


  • Abdominal Pain
  • Bloating
  • Diarrhea
  • Vomiting
  • Nausea
  • Constipation


  • Tablet
  • Injection

     Route of Administration

  • Oral
  • Intravenous


  • Clinic
  • Hospital

     Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

     Drug Class

  • Antibiotic
  • Antidepressants
  • Antidiarrheal

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Intestinal Pseudo-obstruction Treatment Industry - Regional Synopsis

North American Market Statistics

The intestinal pseudo-obstruction treatment market in the North America region will have the biggest growth during the forecast period with a revenue share of around 45%. This growth will be noticed owing to the increasing advancement in the tools of diagnosis in this region. An American Medical Association investigation demonstrated that 57% of physicians utilize or plan to utilize digital clinical support equipment in their work. The clinical determination support resource UpToDate is utilized in more than 190 countries and by 90% of US academic medical centers. Unifying this equipment into practice, specifically in sub-Saharan Africa, is a significant element of modifying the complete quality of healthcare. However, substantial gaps exist in the utilization of these gadgets in healthcare providers' routine exercises in low-resource settings.

European Market Analysis

The intestinal pseudo-obstruction treatment market in the Europe region will also encounter huge growth during the forecast period and will hold the second position owing to the chronic digestive disease in this region. The chronic disease management is mostly common in European countries. More than 332 million people are anticipated to be living with a digestive disorder in the European region, in line with a report from the United European Gastroenterology (UEG). In an assessment of the epidemiology of digestive situations around 44 UEG member countries, the report recommends that, between 2000 and 2019, the age-standardized prevalence of digestive diseases enhanced only slightly, but as an outcome of modified survival, age-standardized frequency enhanced by 5%. Chronic liver disorders, pancreatitis, and gastro-oesophageal reflux disease (GORD) were among the digestive situations for which age-standardized incidence or age-standardized frequency had enhanced since 2000.

Research Nester
Intestinal Pseudo-obstruction Treatment Market  size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Intestinal Pseudo-obstruction Treatment Market

    • GlaxoSmithKline Plc.
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • Pfizer Inc.
    • Johnson & Johnson
    • Callisto Pharmaceuticals Inc.
    • Biogen Inc.
    • Novartis A.G
    • Canila Healthcare Ltd
    • AbbVie Inc.
    • Eli Lilly and Company


In The News

GSK Plc. declared that it has fulfilled the acquirement of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical organization concentrated on tackling the unmet treatment requirements of patients with respiratory and inflammatory situations.

GSK Plc. declared that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved for review the regulatory application of Shingrix for the prohibition of shingles (herpes zoster) in adults aged 18 years and more than at growing risk.


Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5760
  • Published Date: Feb 29, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increased frequency of gastrointestinal disease will majorly drive the market growth of the intestinal pseudo-obstruction treatment market.

The market size of the intestinal pseudo-obstruction treatment market is expected to get a CAGR of approximately 5% over the forecast period, i.e., 2024-2036.

The major players in the market are GlaxoSmithKline Plc., Abbott Laboratories, Pfizer Inc., Johnson & Johnson, Callisto Pharmaceuticals Inc., Biogen Inc., Novartis A.G., Canila Healthcare Ltd, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited., Daiichi Sankyo Co Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co Ltd.

The antibiotics segment is anticipated to reap the largest market size with almost 68% by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Intestinal Pseudo-obstruction Treatment Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying